Drug Trial Radar · NCT00268476
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
Last checked: Nov 19, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
11,992
Actual
Start
Jul 8, 2005
Primary completion
Mar 2026
Study completion Dec 2030
Sponsor
- Lead sponsor
- Medical Research CouncilGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Dec 22, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall aim of this trial, which is called STAMPEDE, is to assess novel approaches for the treatment of men with prostate cancer who are starting long-term ADT for the first time, termed hormone-naïve prostate cancer. This trial aims to see if we can improve the way in which prostate cancer is currently managed, either by adding new treatments to the standard approach or by modifying the type of hormone therapy aiming to improve quality-of-life by reducing the side effects of treatment. Each new treatment approach is compared against a control arm receiving the current standard treatments. We aim to identify treatment strategies that enable men to live longer, or as long but with an improved quality-of-life, as well as offering value for money for the health service. Since opening to accrual in Oct-2005, the trial has tested many ways of treating prostate cancer and some results are now already known. More than 10,000 men will join the trial with answers becoming available throughout the trial. New patients joining the trial from Protocol version 17.0 onwards (activated in December 2018) may be eligible to join one of two treatment comparisons, metformin (treatment group K; the "metformin comparison") and transdermal oestradiol (treatment group L; the "transdermal oestradiol comparison"). A computer program will be used to allocate which treatment each participant receives, using a chance process. Summary of the research arms in STAMPEDE trial platform Summary of research treatment groups currently open to recruitment (June 2017) 1. Metformin (Arm K): This anti-diabetic medication is proposed to have both anti-cancer effects and may help prevent the adverse metabolic effects of long-term ADT. STAMPEDE will investigate whether adding metformin to the current standard-of-care for non-diabetic men can improve all-cause survival. 2. Transdermal oestradiol (Arm L): This is an alternative form of hormone treatment which has been shown to suppress testosterone as effectively as standard ADT and avoid some of the side-effects. It may also help to avoid the adverse metabolic effects and fatigue and therefore improve overall quality of life compared with standard forms of ADT. STAMPEDE will investigate whether transdermal oestradiol can treat the cancer as well as current standard forms of ADT. 3. Control group (Arm A): Patients allocated to this group receive the current standard-of-care ADT +/- RT +/- docetaxel.
Conditions
- Prostate Cancer
Interventions
CelecoxibDrug
DocetaxelDrug
PrednisoloneDrug
ADTDrug
Zoledronic AcidDrug
AbirateroneDrug
Radiotherapy to the prostateRadiation
EnzalutamideDrug
MetforminDrug
Transdermal OestradiolDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survivalTime frame: 1:Not applicable
Locations
120 sites in 2 countries. Site status is shown where the registry gives one.
Hirslanden Klinik Aarau
Aarau, Switzerland
Universitaetsspital-Basel
Basel, Switzerland
Inselspital Bern
Bern, Switzerland
Liestal Hospital
Liestal, Switzerland
Kantonsspital - St. Gallen
Sankt Gallen, Switzerland
UniversitaetsSpital Zuerich
Zurich, Switzerland
City Hospital Triemli
Zurich, Switzerland
Lausanne Centre Hospitalier Universitaire
Lausanne, Canton of Vaud, Switzerland
Winterthur Hospital
Winterthur, Canton of Zurich, Switzerland
Kantonsspital Graubuenden
Chur, Kanton Graubünden, Switzerland
Barnet General Hospital
Barnet, United Kingdom
Colchester General Hospital
Colchester, United Kingdom
Forth Valley Hospital
Larbert, United Kingdom
Lincoln Hospital
Lincoln, United Kingdom
North Tees Hospital
Stockton-on-Tees, United Kingdom
New Cross Hospital
Wolverhampton, United Kingdom
Berkshire Cancer Centre at Royal Berkshire Hospital
Reading, Berkshire, United Kingdom
Royal Bolton Hospital
Farnworth, Bolton, United Kingdom
Wycombe General Hospital
High Wycombe, Buckinghamshire, United Kingdom
Addenbrooke's Hospital
Cambridge, Cambridgeshire, United Kingdom
Broomfield Hospital
Broomfield, Chelmsford, United Kingdom
Countess of Chester Hospital
Chester, Chesire, United Kingdom
James Cook University Hospital
Middlesbrough, County Durham, United Kingdom
Cumberland Infirmary
Carlisle, Cumbria, United Kingdom
North Devon District Hospital
Barnstaple, Devon, United Kingdom
Royal Devon and Exeter Hospital
Exeter, Devon, United Kingdom
Royal Bournemouth Hospital
Bournemouth, Dorset, United Kingdom
Dorset County Hospital
Dorchester, Dorset, United Kingdom
Poole Hospital
Poole, Dorset, United Kingdom
Castle Hill Hospital
Cottingham, East Riding Of Yorkshire, United Kingdom
Eastbourne District General Hospital
Eastbourne, East Sussex, United Kingdom
Conquest Hospital
Saint Leonards-on-Sea, East Sussex, United Kingdom
William Harvey Hospital
Ashford, England, United Kingdom
Stoke Mandeville Hospital
Aylesbury, England, United Kingdom
Basingstoke and North Hampshire NHS Foundation Trust
Basingstoke, England, United Kingdom
City Hospital (Birmingham)
Birmingham, England, United Kingdom
Sussex Cancer Centre at Royal Sussex County Hospital
Brighton, England, United Kingdom
Burnley General Hospital
Burnley, England, United Kingdom
Queen's Hospital
Burton-on-Trent, England, United Kingdom
West Suffolk Hospital
Bury St Edmunds, England, United Kingdom
Showing 40 of 120 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.